Correlation between triglyceride-glucose index and diabetic kidney disease risk in adults with type 1 diabetes mellitus

Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119:154770. 10.1016/j.metabol.2021.154770

[2]

The Product of Fasting Glucose and Triglycerides As Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects

Luis E. Simental-Mendía, Martha Rodríguez-Morán, Fernando Guerrero-Romero

Metabolic Syndrome and Related Disorders 2008 10.1089/met.2008.0034

[3]

Yang Y, Huang X, Wang Y, et al. The impact of triglyceride-glucose index on ischemic stroke: a systematic review and meta-analysis. Cardiovasc Diabetol. 2023;22(1):2. 10.1186/s12933-022-01732-0

[4]

Khalaji A, Behnoush AH, Khanmohammadi S, et al. Triglyceride-glucose index and heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2023;22(1):244. 10.1186/s12933-023-01973-7

[5]

Liang S, Wang C, Zhang J, et al. Triglyceride-glucose index and coronary artery disease: a systematic review and meta-analysis of risk, severity, and prognosis. Cardiovasc Diabetol. 2023;22(1):170. 10.1186/s12933-023-01906-4

[6]

Ren X, Jiang M, Han L, Zheng X. Association between triglyceride-glucose index and chronic kidney disease: a cohort study and meta-analysis. Nutr Metab Cardiovasc Dis. 2023;33(6):1121–8. 10.1016/j.numecd.2023.03.026

[7]

Behnoush AH, Khalaji A, Ghondaghsaz E, et al. Triglyceride-glucose index and obstructive sleep apnea: a systematic review and meta-analysis. Lipids Health Dis. 2024;23(1):4. 10.1186/s12944-024-02005-3

[8]

Azarboo A, Behnoush AH, Vaziri Z, et al. Assessing the association between triglyceride-glucose index and atrial fibrillation: a systematic review and meta-analysis. Eur J Med Res. 2024;29(1):118. 10.1186/s40001-024-01716-8

[9]

Kassab HS, Osman NA, Elrahmany SM. Assessment of triglyceride-glucose index and ratio in patients with type 2 diabetes and their relation to Microvascular complications. Endocr Res. 2023;48(4):94–100. 10.1080/07435800.2023.2245909

[10]

Girgis CM, Scalley BD, Park KE. Utility of the estimated glucose disposal rate as a marker of microvascular complications in young adults with type 1 diabetes. Diabetes Res Clin Pract. 2012;96(3):e70–2. 10.1016/j.diabres.2012.02.004

[11]

Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: double diabetes in the Diabetes Control and complications Trial. Diabetes Care. 2007;30(3):707–12. 10.2337/dc06-1982

[12]

Liu L, Yang D, Zhang Y, et al. Glycaemic control and its associated factors in Chinese adults with type 1 diabetes mellitus. Diabetes Metab Res Rev. 2015;31(8):803–10. 10.1002/dmrr.2716

[13]

Beck RW, Tamborlane WV, Bergenstal RM, et al. The T1D Exchange clinic registry. J Clin Endocrinol Metab. 2012;97(12):4383–9. 10.1210/jc.2012-1561

[14]

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Francesco Cosentino, Peter J Grant, Victor Aboyans et al.

European Heart Journal 10.1093/eurheartj/ehz486

[15]

The Product of Triglycerides and Glucose, a Simple Measure of Insulin Sensitivity. Comparison with the Euglycemic-Hyperinsulinemic Clamp

Fernando Guerrero-Romero, Luis E. Simental-Mendía, Manuel González-Ortiz et al.

The Journal of Clinical Endocrinology & Metabo... 2010 10.1210/jc.2010-0288

[16]

Greci LS, Kailasam M, Malkani S, et al. Utility of HbA(1c) levels for diabetes case finding in hospitalized patients with hyperglycemia. Diabetes Care. 2003;26(4):1064–8. 10.2337/diacare.26.4.1064

[17]

Modified Glomerular Filtration Rate Estimating Equation for Chinese Patients with Chronic Kidney Disease

Ying-Chun Ma, Li Zuo, Jiang-Hua Chen et al.

Journal of the American Society of Nephrology 2006 10.1681/asn.2006040368

[18]

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey, Lesley A. Stevens, Christopher H. Schmid et al.

Annals of Internal Medicine 10.7326/0003-4819-150-9-200905050-00006

[19]

Zheng X, Huang B, Luo S, Yang D, Bao W, Li J, et al. A new model to estimate insulin resistance via clinical parameters in adults with type 1 diabetes. Diabetes Metab Res Rev. 2017;33(4). 10.1002/dmrr.2880

[20]

Mu X, Wu A, Hu H, Yang M, Zhou H. Correlation between alternative insulin resistance indexes and diabetic kidney disease: a retrospective study. Endocrine. 2024;84(1):136–47. 10.1007/s12020-023-03574-6

[21]

Huang Q, Yang D, Deng H, et al. Association between metabolic syndrome and microvascular complications in Chinese adults with type 1 diabetes Mellitus. Diabetes Metab J. 2022;46(1):93–103. 10.4093/dmj.2020.0240

[22]

Merger SR, Kerner W, Stadler M, et al. Prevalence and comorbidities of double diabetes. Diabetes Res Clin Pract. 2016;119:48–56. 10.1016/j.diabres.2016.06.003

[23]

Davis TM, Bruce DG, Davis WA. Prevalence and prognostic implications of the metabolic syndrome in community-based patients with type 1 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract. 2007;78(3):412–7. 10.1016/j.diabres.2007.06.007

[24]

Pathak V, Mishra I, Baliarsinha AK, Choudhury AK. Prevalence of Insulin Resistance in type 1 diabetes Mellitus and its correlation with metabolic parameters: the double trouble. Eurasian J Med. 2022;54(2):107–12. 10.5152/eurasianjmed.2022.21039

[25]

Donga E, Dekkers OM, Corssmit EP, Romijn JA. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol. 2015;173(1):101–9. 10.1530/eje-14-0911

[26]

Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes. 2000;49(4):626–32. 10.2337/diabetes.49.4.626

[27]

Szadkowska A, Pietrzak I, Mianowska B, Markuszewski L, Bodalska-Lipińska J, Bodalski J. Wskaźnik insulinooporności u dzieci i młodziezy chorej na cukrzyce typu 1 -- uproszczony sposób oceny [Insulin resistance in type 1 diabetic children and adolescents -- a simplified method of estimation]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006;12(2):109–15.

[28]

Thorn LM, Forsblom C, Fagerudd J, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005;28(8):2019–24. 10.2337/diacare.28.8.2019

[29]

Committee MW, Bonadonna R, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care. 2006;29(12):2701–7. 10.2337/dc06-0942

[30]

Bhagadurshah RR, Eagappan S, Kasthuri Santharam R, Subbiah S. The impact of body Mass Index, residual Beta cell function and estimated glucose disposal rate on the development of double diabetes and microvascular complications in patients with type 1 diabetes Mellitus. Cureus. 2023;15(11):e48979.

[31]

Insulin Resistance in Type 1 Diabetes Mellitus and Its Association with Patient’s Micro- and Macrovascular Complications, Sex Hormones, and Other Clinical Data

Diana Šimonienė, Aksana Platūkiene, Edita Prakapienė et al.

Diabetes Therapy 2020 10.1007/s13300-019-00729-5

[32]

Hukportie DN, Li FR, Zhou R, et al. Lipid variability and risk of microvascular complications in action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: a post hoc analysis. J Diabetes. 2022;14(6):365–76. 10.1111/1753-0407.13273

[33]

Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development

Hyun Mi Kang, Seon Ho Ahn, Peter Choi et al.

Nature Medicine 2015 10.1038/nm.3762

[34]

Martin WP, Nair M, Chuah YHD, et al. Dietary restriction and medical therapy drives PPARα-regulated improvements in early diabetic kidney disease in male rats. Clin Sci (Lond). 2022;136(21):1485–511. 10.1042/cs20220205

[35]

Fegan PG, Shore AC, Mawson D, Tooke JE, MacLeod KM. Microvascular endothelial function in subjects with type 2 diabetes and the effect of lipid-lowering therapy. Diabet Med. 2005;22(12):1670–6. 10.1111/j.1464-5491.2005.01719.x

[36]

Sacks FM. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol. 2008;102(12A):34L-40L. 37. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G 10.1016/j.amjcard.2008.09.073

[37]

DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45(3):485-493. 10.1053/j.ajkd.2004.11.004

Metrics

6

Citations

37

References

Details

Published: Oct 01, 2024
Vol/Issue: 16(1)
License: View

Authors

23Center for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Funding

Diabetes Mellitus Research Fund Program from Shanghai Medical and Health Development Foundation Award: DMRFP_II_14 from SHMHDF

National Key R&D Program of China 2023 Award: SQ2023AAA030344

Cite This Article

Mengyun Lei, Ping Ling, Yongwen Zhou, et al. (2024). Correlation between triglyceride-glucose index and diabetic kidney disease risk in adults with type 1 diabetes mellitus. Diabetology & Metabolic Syndrome, 16(1). https://doi.org/10.1186/s13098-024-01468-9

Correlation between triglyceride-glucose index and diabetic kidney disease risk in adults with type 1 diabetes mellitus

You May Also Like